Abstract B162: NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models

Neil o Carragher; Sweta Dash; Katherine Nyswaner; Mungo j b Harvey; Ben King; Allison Woods; Asier Unciti-Broceta; Enrique Poradosu; John Brognard

doi:10.1158/1535-7163.TARG-23-B162

Abstract B162: NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models

Neil o Carragher, Sweta Dash, Katherine Nyswaner, Mungo j b Harvey, Ben King, Allison Woods, Asier Unciti-Broceta, Enrique Poradosu, John Brognard

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	B162-B162
Journal	Molecular Cancer Therapeutics
Volume	22
Issue number	12_Supplement
DOIs	https://doi.org/10.1158/1535-7163.TARG-23-B162
Publication status	Published - 1 Dec 2023

Access to Document

10.1158/1535-7163.TARG-23-B162

https://aacrjournals.org/mct/article/22/12_Supplement/B162/730742/Abstract-B162-NXP900-a-novel-YES1-SRC-kinase

Cite this

Carragher, N. O., Dash, S., Nyswaner, K., Harvey, M. J. B., King, B., Woods, A., Unciti-Broceta, A., Poradosu, E., & Brognard, J. (2023). Abstract B162: NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models. Molecular Cancer Therapeutics, 22(12_Supplement), B162-B162. https://doi.org/10.1158/1535-7163.TARG-23-B162

@article{1244a999466c469cb47e7ad1627b9592,

title = "Abstract B162: NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models",

author = "Carragher, {Neil o} and Sweta Dash and Katherine Nyswaner and Harvey, {Mungo j b} and Ben King and Allison Woods and Asier Unciti-Broceta and Enrique Poradosu and John Brognard",

year = "2023",

month = dec,

day = "1",

doi = "10.1158/1535-7163.TARG-23-B162",

language = "English",

volume = "22",

pages = "B162--B162",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "12_Supplement",

}

Carragher, NO, Dash, S, Nyswaner, K, Harvey, MJB, King, B, Woods, A, Unciti-Broceta, A, Poradosu, E & Brognard, J 2023, 'Abstract B162: NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models', Molecular Cancer Therapeutics, vol. 22, no. 12_Supplement, pp. B162-B162. https://doi.org/10.1158/1535-7163.TARG-23-B162

Abstract B162: NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models. / Carragher, Neil o; Dash, Sweta; Nyswaner, Katherine et al.
In: Molecular Cancer Therapeutics, Vol. 22, No. 12_Supplement, 01.12.2023, p. B162-B162.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Abstract B162: NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models

AU - Carragher, Neil o

AU - Dash, Sweta

AU - Nyswaner, Katherine

AU - Harvey, Mungo j b

AU - King, Ben

AU - Woods, Allison

AU - Unciti-Broceta, Asier

AU - Poradosu, Enrique

AU - Brognard, John

PY - 2023/12/1

Y1 - 2023/12/1

U2 - 10.1158/1535-7163.TARG-23-B162

DO - 10.1158/1535-7163.TARG-23-B162

M3 - Article

SN - 1535-7163

VL - 22

SP - B162-B162

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 12_Supplement

ER -